Human protein C zymogen concentrate in patients with severe sepsis and multiple organ failure after adult cardiac surgery

Intensive Care Med. 2009 Nov;35(11):1959-63. doi: 10.1007/s00134-009-1584-3. Epub 2009 Aug 1.

Abstract

Purpose: To describe outcome and changes in clotting and inflammatory parameters in an uncontrolled case series of consecutive patients with severe sepsis who received protein C concentrate soon after cardiac surgery.

Methods: From January 2007 to January 2008 nine consecutive adult patients with severe sepsis or septic shock and two or more organ failure after cardiac surgery received protein C concentrate, 50 IU/kg as a bolus followed by continuous infusion of 3 IU/kg per hour for 72 h.

Results: The increase in protein C levels was accompanied by an early drop in interleukins and near-normalization of prothrombin time, activated partial thromboplastin time, antithrombin and thrombin-antithrombin complex levels (p < or = 0.03). No patient experienced drug-related side effects. Thirty-day mortality was 11% (1 patient) compared to the expected mortality of 68%.

Conclusions: In this pilot, uncontrolled study of nine patients with sepsis-induced double organ failure following cardiac surgery, treatment with protein C concentrate was associated with significant improvement in clinical, inflammatory and clotting parameters, no bleeding and low 30-day mortality.

Publication types

  • Clinical Trial

MeSH terms

  • Aged
  • Antithrombin III / drug effects
  • Antithrombins / drug effects
  • Antithrombins / metabolism
  • Cardiac Surgical Procedures / adverse effects*
  • Female
  • Fibrinolytic Agents / metabolism
  • Fibrinolytic Agents / therapeutic use*
  • Humans
  • Infusions, Intravenous
  • Injections, Intravenous
  • Interleukins / blood
  • Italy / epidemiology
  • Male
  • Middle Aged
  • Multiple Organ Failure / blood
  • Multiple Organ Failure / drug therapy*
  • Multiple Organ Failure / etiology
  • Multiple Organ Failure / mortality
  • Partial Thromboplastin Time
  • Peptide Hydrolases / blood
  • Peptide Hydrolases / drug effects
  • Pilot Projects
  • Postoperative Care
  • Protein C / metabolism
  • Protein C / therapeutic use*
  • Prothrombin Time
  • Sepsis / blood
  • Sepsis / drug therapy*
  • Sepsis / etiology
  • Sepsis / mortality
  • Time Factors
  • Treatment Outcome

Substances

  • Antithrombins
  • Fibrinolytic Agents
  • Interleukins
  • Protein C
  • antithrombin III-protease complex
  • Antithrombin III
  • Peptide Hydrolases